Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06320223Recruiting
PSMA PET scan registry for prostate cancer outcomes
This registry collects information from people with prostate cancer who have had a PSMA PET scan. Researchers want to learn how well this scan predicts outcomes over at least 3 years, which may help improve future care.
EssenAges 18 years+ - NCT06335693Recruiting
Short-course radiation after prostate surgery
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT05646550RecruitingPhase 1
Antibody CC-1 for men with returning prostate cancer
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
TübingenAges 18 years+ - NCT07853209RecruitingPhase 3
A study of a radioactive drug for men with metastatic prostate cancer
This study tests a new radioactive drug (called [177Lu]Ludotadipep) that targets a molecule on prostate cancer cells. It may help slow cancer growth in men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy.
Gyeonggi-doAges 19 years+ - NCT07847385Recruiting
MRI-guided nerve-sparing for prostate cancer surgery
This study tests whether using special MRI scans to map nerves before surgery helps keep erectile function after prostate removal. It may help men who are having surgery for prostate cancer and want to preserve sexual function.
Geneva, Canton of GenevaAges 18 years+ - NCT07831824RecruitingPhase 2/Phase 3
Imaging drug to find prostate cancer spread before or after treatment
This trial tests an imaging agent that helps find cancer that has spread beyond the prostate, either when first diagnosed or if it comes back after treatment. The goal is to see what dose works best for clear pictures.
Grand Rapids, MichiganAges 18 years+ - NCT06473259Recruiting
Comparing treatments for hormone-sensitive metastatic prostate cancer
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Orbassano, TorinoAges Any age - NCT07820566Recruiting
Personalized 3D tumor model for kidney, bladder, and prostate cancers
This study uses your tumor sample to build a personalized 3D model that mimics how your cancer grows. The goal is to better understand these cancers and potentially find more effective treatments in the future.
StrasbourgAges 18 years+ - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT06491056Recruiting
Focal therapy study for prostate cancer in Asia
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
SingaporeAges 40–85 - NCT07813637RecruitingPhase 1
Testing a combination of two new drugs for advanced prostate cancer
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07801664RecruitingPhase 2
Short course hormone therapy for prostate cancer
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
New York, New YorkAges 18 years+ - NCT06518226Recruiting
Ultra-short radiation with focal boost for prostate cancer
This trial tests a new, shorter course of radiation for intermediate-risk prostate cancer. It aims to give a higher dose to the main tumor while keeping side effects low.
UtrechtAges 18 years+ - NCT07792590Recruiting
Focal therapy registry for prostate cancer
This study is a registry for people who have already had focal therapy (targeted treatment) for prostate cancer at Queen Mary Hospital. It aims to collect information about these treatments, which may help improve future care.
Hong Kong, Hong KongAges 18 years+ - NCT07790718Recruiting
Exercise program to prevent colorectal cancer after prostate radiation
This study tests whether an exercise program can help prevent colorectal cancer in men who have had pelvic radiation for prostate cancer. It involves using an iPhone app to track activity and attending exercise sessions.
Duarte, CaliforniaAges 40–80 - NCT07788625Recruiting
Focal therapy for prostate cancer not visible on MRI
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
Hong Kong, 香港島Ages 50 years+ - NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT06575257RecruitingPhase 2
Darolutamide and Hormone Therapy Before Prostate Surgery
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
Xi’an, ShanxiAges 18–75 - NCT07751159RecruitingPhase 2
Comparing radiation therapy methods for prostate cancer
This study compares two types of radiation therapy for prostate cancer that hasn't spread. It aims to find which approach is more effective and has fewer side effects.
Basking Ridge, New JerseyAges Any age - NCT07757490Recruiting
Sonablate HIFU registry for prostate cancer and BPH
This study is a registry that collects information from men who have had Sonablate HIFU treatment for prostate cancer or enlarged prostate (BPH). It will help doctors learn more about how well this treatment works in real life.
Indianapolis, IndianaAges 18 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07735377RecruitingPhase 1
Study of SHR-6914 for Prostate Cancer
This study tests a new drug called SHR-6914 in men with prostate cancer that has spread. The goal is to see if it is safe and helps shrink or control the cancer, and to learn how the body processes it.
Guangzhou, GuangdongAges 18–80 - NCT05946824RecruitingPhase 2
Radiation for prostate cancer that returned after surgery
This trial tests a new way of delivering radiation for prostate cancer that has come back after prostate surgery. It may help control the cancer by targeting the “prostate bed” area or nearby lymph nodes where it returned.
Rochester, New YorkAges 18 years+
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.